Ibrutinib-venetoclax effective in previously untreated chronic lymphocytic leukaemia

A recent study found that ibrutinib-venetoclax continues to demonstrate its effectiveness in prolonging progression-free survival versus chemoimmunotherapy in previously untreated chronic lymphocytic leukaemia patients. This study’s findings were published in the journal, The Lancet. Oncology.

In the GLOW study, a phase 3 randomised, multicentre clinical trial, 211 patients with previously untreated chronic lymphocytic leukaemia were enrolled. These patients were randomly divided into two groups: the ibrutinib-venetoclax group (n=106) and the chlorambucil-obinutuzumab group (n=105). The primary endpoint of the study was to assess the progression-free survival of the patients, which was evaluated by an independent review committee.

The ibrutinib-venetoclax group showed better progression-free survival at a median of 46 months of follow-up (hazard ratio of 0.214). The 42-month progression-free survival rates were 74.6% for ibrutinib-venetoclax and 24.8% for chlorambucil-obinutuzumab.

To summarize, after a 4-year period of follow-up, ibrutinib-venetoclax continues to demonstrate a significant increase in progression-free survival compared to chemoimmunotherapy for patients with previously untreated chronic lymphocytic leukemia, supporting its use as a suitable first-line treatment option.